Waldenstrom Macroglobulinemia Research Offers New Hope for Patients

Researchers at the Dana-Farber Cancer Institute have made significant discoveries in the field of Waldenstrom macroglobulinemia, a rare blood disorder. According to a new report, mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in patients with WM. The study, supported by the International Waldenstrom's Macroglobulinemia Foundation, aims to improve treatment options for patients.

Key Takeaways:

Mutations in MYD88 and CXCR4 are prevalent in patients with Waldenstrom macroglobulinemia, with 95%-97% and 30%-40% of patients affected, respectively.
TP53 is also altered in up to 30% of WM patients, particularly those previously treated.
The mutated MYD88 triggers the expression and activation of HCK, driving multiple pro-survival signaling cascades, including BTK.
There are over 40 CXCR4 mutation types in WM, with patients bearing nonsense CXCR4 variants showing greater resistance to covalent BTK inhibitors (cBTK-i).
Zanubrutinib, a cBTK-i, shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53.
Emerging treatment options include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax, as well as combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists.
Algorithms for patients with treatment-naive and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed.

Statistics:

95%-97% of patients with Waldenstrom macroglobulinemia have mutations in MYD88.
30%-40% of patients with WM have mutated CXCR4.
30% of WM patients have altered TP53.
Over 40 CXCR4 mutation types exist in WM.

Sources:

"Diagnosis and Management of Waldenstrom's Macroglobulinemia. Hematological Oncology, 2025;43." (Wiley-Blackwell - www.wiley.com/; Hematological Oncology - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1069)
Immunotherapy Weekly. July 9, 2025; p 4541.